Janssen (United Kingdom)

Recent papers from Janssen (United Kingdom)

1. Evaluating the Impact of Outcome Delay on the Efficiency of Sample Size Re‐EstimationPharmaceutical Statistics · 2026
2. Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE studyHaematologica · 2026
3. Optimising fall risk classification models in Parkinson's disease using clinical and mobility outcomesParkinsonism & Related Disorders · 2026
4. Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUSBlood Advances · 2026
5. Laboratory-based turning performance during walking in people with mild cognitive impairment and dementiaJournal of Alzheimer s Disease · 2026
6. Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trialChinese Medical Journal · 2026
7. Randomisation methods in a multi-arm multi-stage platform trial designResearch Methods in Medicine & Health Sciences · 2026
8. Impact of baseline hot flashes on sleep metrics during initial treatment in LIBERTAS clinical trial.Journal of Clinical Oncology · 2026
9. The role of subtyping methodologies in HIV surveillance and vaccine development: a systematic review and meta-analysisAIDS · 2025
10. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON StudyTargeted Oncology · 2025
11. The role of cytochrome bc1 inhibitors in future tuberculosis treatment regimensNature Communications · 2025
12. Practical guide to management after an acute pulmonary embolismBMJ Open Respiratory Research · 2025
13. Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignanciesFuture Science OA · 2025
14. Operationalizing Decentralized Clinical Trials: Technology Insights from the Trials@Home RADIAL Proof‐of‐Concept TrialClinical Pharmacology & Therapeutics · 2025
15. Changes in depression medication following the initial assessment by specialised psychiatry services in the Helsinki-Uusimaa RegionEuropean Psychiatry · 2025
16. Improvements in Functioning with Esketamine Nasal Spray versus Quetiapine Extended Release in Patients with Treatment Resistant DepressionEuropean Psychiatry · 2025
17. Outcomes with esketamine nasal spray in patients with or without earlier partial or full response: post hoc analyses of ESCAPE TRDEuropean Psychiatry · 2025
18. Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.2025
19. Confidence Intervals for Adaptive Trial Designs I: A Methodological ReviewStatistics in Medicine · 2025
20. Confidence Intervals for Adaptive Trial Designs II: Case Study and Practical GuidanceStatistics in Medicine · 2025